Published in Gynecol Oncol on August 01, 2003
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol (2004) 6.20
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
Ovarian cancer. Annu Rev Pathol (2009) 4.92
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol (2009) 3.90
Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol (2008) 3.22
Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol (2008) 2.60
Selective expression of KrasG12D in granulosa cells of the mouse ovary causes defects in follicle development and ovulation. Development (2008) 1.68
Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS One (2007) 1.56
Association of decreased mitochondrial DNA content with ovarian cancer progression. Br J Cancer (2006) 1.43
Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer (2008) 1.38
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer (2009) 1.33
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol (2010) 1.26
Uterine disorders and pregnancy complications: insights from mouse models. J Clin Invest (2010) 1.17
Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int (2014) 1.11
Ovarian cancer update: lessons from morphology, molecules, and mice. Arch Pathol Lab Med (2009) 1.09
Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer (2009) 1.08
Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod (2013) 1.06
C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy). Cancer Causes Control (2009) 0.99
Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark (2010) 0.95
Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep (2014) 0.95
Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol (2010) 0.91
Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem (2012) 0.89
Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers. PLoS One (2014) 0.88
Mitochondrial DNA content varies with pathological characteristics of breast cancer. J Oncol (2011) 0.88
Precursors of endometrial and ovarian carcinoma. Virchows Arch (2009) 0.88
Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene (2005) 0.86
Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Diagn Pathol (2013) 0.85
Ovarian cancer: genomic analysis. Ann Oncol (2013) 0.84
Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma. PLoS One (2013) 0.83
Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol (2012) 0.83
Activation of the MEK-S6 pathway in high-grade ovarian cancers. Appl Immunohistochem Mol Morphol (2010) 0.82
Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. Virchows Arch (2014) 0.81
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med (2016) 0.81
Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer (2015) 0.80
Genetic and molecular changes in ovarian cancer. Cancer Biol Med (2016) 0.78
TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis? Hum Pathol (2016) 0.77
Ovarian cancer stroma: pathophysiology and the roles in cancer development. Cancers (Basel) (2012) 0.77
[Molecular pathology of epithelial ovarian neoplasias: from the phenotype-genotype correlation to new targets in diagnostics and therapy]. Pathologe (2007) 0.77
Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones. Cancer Res (2016) 0.77
Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gynecol Oncol Res Pract (2015) 0.76
The molecular background of mucinous carcinoma beyond MUC2. J Pathol Clin Res (2014) 0.76
Trismus and diffuse polymyalgia: an unusual presentation of recurrent metastatic ovarian cancer. BMJ Case Rep (2014) 0.75
Morphological and molecular basis of ovarian serous carcinoma. J Biomed Res (2010) 0.75
Subtypes of Ovarian Cancer and Ovarian Cancer Screening. Diagnostics (Basel) (2017) 0.75
Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. Int J Mol Sci (2016) 0.75
Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol (2017) 0.75
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A (2008) 4.76
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res (2005) 4.14
A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res (2008) 4.05
Accidental hypothermia. N Engl J Med (2012) 4.01
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst (2002) 3.40
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol (2004) 2.91
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol (2002) 2.80
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res (2005) 2.72
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol (2009) 2.45
Radical trachelectomy and pelvic lymphadenectomy with uterine preservation in the treatment of cervical cancer. Am J Obstet Gynecol (2003) 2.25
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol (2007) 2.19
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res (2002) 2.16
The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecol Oncol (2008) 2.14
Incidence of venous thromboembolism after minimally invasive surgery in patients with newly diagnosed endometrial cancer. Obstet Gynecol (2012) 2.09
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res (2003) 2.09
Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid (2014) 2.04
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer (2006) 2.03
TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol (2011) 1.94
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol (2013) 1.92
Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res (2005) 1.86
Implication of snoRNA U50 in human breast cancer. J Genet Genomics (2009) 1.80
Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults. Am J Surg Pathol (2007) 1.79
Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys (2005) 1.77
Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature. Gynecol Oncol (2006) 1.73
Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer (2013) 1.71
Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma : a Gynecologic Oncology Group study. Cancer (2006) 1.71
Subcutaneous tumor implantation after laparoscopic procedures in women with malignant disease. Obstet Gynecol (2004) 1.69
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res (2009) 1.68
Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol (2005) 1.64
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol (2006) 1.64
Comparison of avalanche survival patterns in Canada and Switzerland. CMAJ (2011) 1.62
Molecular profiling of endometrial cancers from African-American and Caucasian women. Gynecol Oncol (2005) 1.62
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol (2004) 1.60
The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? Int J Gynecol Cancer (2011) 1.60
Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res (2003) 1.56
Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecol Oncol (2011) 1.55
Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol (2007) 1.54
Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. BMC Genet (2008) 1.53
The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol (2012) 1.52
The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol (2006) 1.51
Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer. Gynecol Oncol (2012) 1.47
Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res (2005) 1.46
Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat (2002) 1.44
Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol (2007) 1.44
Pilot study prospectively evaluating the use of the measurement of preoperative sonographic endometrial thickness in postmenopausal patients with endometrial cancer. Menopause (2005) 1.43
Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol (2003) 1.43
Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol (2010) 1.42
Ureteroileocecal appendicostomy based urinary reservoir in irradiated and nonirradiated patients. J Urol (2009) 1.38
Myoepithelial cell-rich neoplasms: cytologic features of benign and malignant lesions. Cancer (2004) 1.37
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol (2010) 1.37
Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol (2011) 1.37
Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? Gynecol Oncol (2009) 1.35
The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol (2009) 1.33
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer (2009) 1.32
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer (2011) 1.32
Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol (2005) 1.32
The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol (2007) 1.28
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol (2006) 1.28
Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol (2009) 1.27
Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol (2004) 1.27
Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer (2003) 1.27
Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol (2005) 1.26
Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One (2010) 1.25
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res (2008) 1.25
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol (2009) 1.23
Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol (2007) 1.23
Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? Int J Radiat Oncol Biol Phys (2002) 1.21
Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. Gynecol Oncol (2008) 1.20
ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. Eur Urol (2012) 1.19
A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol Oncol (2011) 1.18
Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol (2006) 1.18
Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiother Oncol (2011) 1.18
A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible? Gynecol Oncol (2004) 1.17
Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. Gynecol Oncol (2008) 1.16
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res (2009) 1.16
Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med (2008) 1.14
Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes Control (2008) 1.14
A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol (2009) 1.14